STAT+: Pharmalittle: FDA advisory panel to decide on Covid-19 boosters; Justice Dept. trustee appeals Purdue bankruptcy deal
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, once again, rather modest. We plan to catch up on our reading, promenade with our official mascot, and catch some outdoor music. And what about you? The time is nearing to pick apples and pumpkins, so why not scout around for a few orchards and patches? You could also stock up on sweaters and socks now that cool weather will soon be approaching. Or simply look in on someone feeling a bit isolated these days. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …
Do most Americans already need Covid-19 booster shots, or at least will they soon? STAT asks. Those questions have been hotly debated in the public square over the past few weeks. But today, these will be debated in a formal setting where the discussion may affect whether the Biden administration carries through on an announced plan to offer adults boosters several months after receiving a second shot of vaccine. While the discussion relates specifically to the Pfizer (PFE) vaccine, it has implications for the future of boosters in general in the U.S. STAT is live-blogging the FDA advisory committee meeting here.
Continue to STAT+ to read the full story…
